0.04
-27.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Karyopharm Therapeutics
From its filings with the US Securities and Exchange Commission
Karyopharm Therapeutics is based in Newton, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker KPTI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $146.1m and a net loss of $196.0m. At that date it held total assets of $108.4m and shareholders' equity of −$292.9m. By business, Product [Member] brought in 78.6% of revenue, followed by License And Other Revenue. at 21.4% and License and Other Revenue [Member] at 2.4%.
Our primary focus is on marketing XPOVIO in its currently approved indications as well as developing and seeking regulatory approval of selinexor as an oral agent targeting multiple high unmet need cancer indications, including our lead clinical programs in myelofibrosis and endometrial cancer and our other late-stage clinical program in multiple myeloma. Depending on the data in our Phase 3 myelofibrosis and/or endometrial cancer programs and the availability of capital resources, we plan to explore opportunities to develop our leading next-generation XPO1 inhibitor, eltanexor, in additional myeloproliferative neoplasms and TP53 wild-type tumors.
The commercialization of XPOVIO in the U.S. is currently supported by sales representatives, nurse liaisons, and a market access team, as well as KaryForward®, an extensive patient and healthcare provider support program. Our commercial efforts are also supplemented by patient support initiatives coordinated by our dedicated network of participating specialty pharmacy providers.
The commercialization of XPOVIO and NEXPOVIO® (selinexor) (the brand name for selinexor in Europe and the United Kingdom (“UK”)) outside of the U.S. is managed by our partners in their respective territories, as described under “Collaborations” below. XPOVIO/NEXPOVIO has received regulatory approvals in various indications in 50 territories and countries outside the U.S. and is commercially available in a growing number of countries as our partners continue to secure reimbursement approvals.
Quoted from its 10-K, filed 13 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Nov 2013
- Employees
- 228
- Website
- karyopharm.com ↗
- Head office
- 85 WELLS AVENUE, NEWTON, MA, 02459
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Richard PaulsonPresident, Chief Executive Officer, Director, since 2020$2.1m
- Ms. Lori MacomberExecutive Vice President, Chief Financial Officer, Treasurer
- Ms. Sohanya ChengExecutive Vice President, Chief Commercial Officer$1.1m
- Mr. Stuart PoultonExecutive Vice President, Chief Development Officer$1.1m
- Dr. Reshma RangwalaExecutive Vice President, Chief Medical Officer$1.1m
- Mr. Michael ManoSenior Vice President, General Counsel, Secretary$2.1m
- Mr. Brendan StrongSenior Vice President - Investor Relations and Corporate Communications
- Mr. Barry GreeneLead Independent Director$161,078
- Mr. Garen BohlinIndependent Director$126,078
- Ms. Christy OligerIndependent Director$126,078
- Dr. Deepika PakianathanIndependent Director$136,078
- Mr. Chen SchorIndependent Director$116,078
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 33
- Social
- 47
- Governance
- 15
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Karyopharm Therapeutics focuses on oncology with FDA-approved XPOVIO for multiple myeloma treatment.
- The company's SINE compounds target nuclear export proteins like XPO1 for cancer therapy.
- Karyopharm employs 432 full-time employees in Newton Center, Massachusetts.
Weaknesses
- Karyopharm's lead compound XPOVIO is limited to multiple myeloma treatment with no other approved indications.
- The company has only one FDA-approved drug, XPOVIO, for oncology treatment.
- Karyopharm's business is heavily dependent on the success of XPOVIO in the US market.
Opportunities
- Karyopharm can expand XPOVIO's use to other cancer types beyond multiple myeloma.
- The company may develop new SINE compounds targeting nuclear export for additional diseases.
- Karyopharm could explore partnerships for global market expansion in the Health Care sector.
Threats
- Karyopharm faces competition from other oncology drug developers in the US market.
- The company's reliance on XPOVIO makes it vulnerable to regulatory changes in the Health Care industry.
- Karyopharm must navigate potential patent expirations for XPOVIO in the future.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.